Study type: In vitro · Status: Verified against declared source

Evidence that the Human Innate Immune Chemical sequence LL-37 may be a Binding Partner of Amyloid-β and Inhibitor of Fibril Assembly.

Journal of Alzheimer's disease : JAD · 2017

Study scale: Not reported

Product or molecular entity relationships

LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Identifying physiologically relevant binding partners of amyloid-β (Aβ) that modulate in vivo fibril formation may yield new insights into Alzheimer's disease (AD) etiology.

Methods

Specific interactions between LL-37 and Aβ (with Aβ in different aggregation states, assessed by capillary electrophoresis) were demonstrated by surface plasmon resonance imaging (SPRi).

Scale or participants

Not reported in the reviewed source.

Key findings

Identifying physiologically relevant binding partners of amyloid-β (Aβ) that modulate in vivo fibril formation may yield new insights into Alzheimer's disease (AD) etiology.

Limitations and uncertainty

Based on this body of evidence, we propose that LL-37 and Aβ42 may be natural binding partners, which implies that balanced (or unbalanced) spatiotemporal expression of the two peptides could impact AD initiation and progression.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.